As argued in earlier reports, the Monsanto acquisition was not a good idea and, in our view, there will be additional provisions for the settlement of the claims. We had been already quite cautious regarding the Q3 numbers, but Crop Science’s unexpectedly weak contribution led to a miss. The figures were also below consensus as there were more negative one-offs than expected, which may have been attributable to the unclear guidance.